Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Shannon Marshall
Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled Through ERK-Dependent Mechanisms
Journal of Immunology
Allergy
Immunology
Related publications
Phase I Study of Nivolumab, an Anti-Pd-1 Antibody, in Patients With Malignant Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
A Phase 1 Study of Anti-TGFβ Receptor Type-Ii Monoclonal Antibody LY3022859 in Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
A Phase I Study of Farletuzumab, a Humanized Anti-Folate Receptor Α Monoclonal Antibody, in Patients With Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
A Phase I First-In-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
First-In-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-Her3 Monoclonal Antibody, in Patients With Metastatic or Advanced HER3-Positive Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase 1 Study of Cetuximab and Lapatinib in Patients With Advanced Solid Tumor Malignancies
Cancer
Cancer Research
Oncology
A Phase I Study of Indoximod in Patients With Advanced Malignancies
Oncotarget
Oncology
Phase I Study of GSK461364, a Specific and Competitive Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Malignancies
Clinical Cancer Research
Cancer Research
Oncology
